뇌졸중 환자에게 아스피린과 클로피도그렐 내성

키워드

참고문헌 (52)

1. "Low molecular weight heparinoid, ORG 10172 (danaparoid), and outcome after acute ischemic stroke: a randomized controlled trial. The Publications Committee for the Trial of ORG 10172 in Acute Stroke Treatment (TOAST) Investigators", JAMA, 279, pp.1265~1272 (1998)
2. European Stroke Initiative Executive Committee; EUSI Writing Committee, "European Stroke Initiative Recommendations for Stroke Management-update 2003", Cerebrovasc Dis, 16, pp.311~337 (2003)
3. Sacco RL, "Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association", American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline, 2006, pp.37, 577~617
4. Young TK, "The population approach to stroke prevention: a Canadian perspective", Clin Invest Med, 26, pp.78~86 (2003)
5. Cotter G, "Lack of aspirin effect: aspirin resistance or resistance to taking aspirin?", Am Heart J, 147, pp.293~300 (2004)
6. Alberts MJ, "Antiplatelet effect of aspirin in patients with cerebrovascular disease", Stroke, 35, pp.175~178 (2004)
7. Mason PJ, "Aspirin resistance: current concepts", Rev Cardiovasc Med, 5, pp.156~163 (2004)
8. Patrono C, "Aspirin resistance: definition, mechanisms and clinical readouts", J Thromb Haemost, 1, pp.1710~1713 (2003)
9. Wiviott SD, "Clopidogrel resistance: a new chapter in a fast-moving story", Circulation, 109, pp.3064~3067 (2004)
10. Cambria-Kiely JA, "Aspirin resistance and genetic polymorphisms", J Thromb Thrombolysis, 14, pp.51~58 (2002)
11. Lau WC, "Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction", Circulation, 107, pp.32~37 (2003)
12. Saw J, "Clopidogrel for the Reduction of Events During Observation Investigators. Lack of adverse clopidogrel-atorvastatin clinical interaction from secondary analysis of a randomized, placebo-controlled clopidogrel trial", Circulation, 108, pp.921~924 (2003)
13. Lotfi A, "TIMI 22 Investigators. High-dose atorvastatin does not negatively influence clinical outcomes among clopidogrel treated acute coronary syndrome patients--a Pravastatin or Atorvastatin Evaluation and Infection Therapy- Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) analysis", Am Heart J, 155, pp.954~958 (2008)
14. Mega JL, "Cytochrome p-450 polymorphisms and response to clopidogrel", N Engl J Med, 360, pp.354~362 (2009)
15. Simon T, "French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators.Genetic determinants of response to clopidogrel and cardiovascular events", N Engl J Med, 360, pp.363~375 (2009)
16. Bang OY, "Prediction of hemorrhagic transformation after recanalization therapy using T2*-permeability magnetic resonance imaging", Ann Neurol, 62, pp.170~176 (2007)
17. Hankey GJ, "Aspirin resistance", BMJ, 328, pp.477~479 (2004)
18. Smith SC Jr, "American College of Cardiology", American Heart Association Task Force on Practice Guidelines; ACC, SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention. ACC, pp.AHA, SCAI 2005 Guideline Update for Percutaneous Coronary Intervention-Summary Article: a Report of the American College of Cardiology[DOI]
19. Seok JI, "Can aspirin resistance be clinically predicted in stroke patients?", Clin Neurol Neurosurg, 110, pp.110~116 (2008)
20. Faraday N, "Relation between atherosclerosis risk factors and aspirin resistance in a primary prevention population", Am J Cardiol, 98, pp.774~779 (2006)
21. Harrison P, "Screening for aspirin responsiveness after transient ischemic attack and stroke: comparison of 2 point-of-care platelet function tests with optical aggregometry", Stroke, 36, pp.1001~1005 (2005)
22. Fitzgerald DJ, "Aspirin and clopidogrel resistance", Hematology Am Soc Hematol Educ Program, 2007, pp.114~120 (2007)
23. Bonello L, "Vasodilator-stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events", J Thromb Haemost, 5, pp.1630~1636 (2007)
24. Frere C, "ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome", Thromb Haemost, 98, pp.838~843 (2007)
25. Aleil B, "Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ischemic cardiovascular diseases", J Thromb Haemost, 3, pp.85~92 (2005)
26. Gurbel PA, "Platelet reactivity in patients and recurrent events post-stenting: results of the PREPARE POST-STENTING Study", J Am Coll Cardiol, 46, pp.1820~1826 (2005)
27. Angiolillo DJ, "Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease", J Am Coll Cardiol, 50, pp.1541~1547 (2007)
28. Cuisset T, "Relation of low response to clopidogrel assessed with point-of-care assay to periprocedural myonecrosis in patients undergoing elective coronary stenting for stable angina pectoris", Am J Cardiol, 101, pp.1700~1703 (2008)
29. Lee DH, "Dual antiplatelet therapy monitoring for neurointerventional procedures using a point-of-care platelet function test: a single-center experience", AJNR Am J Neuroradiol, 29, pp.1389~1394 (2008)
30. Eikelboom JW, "Aspirinresistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events", Circulation, 105, pp.1650~1655 (2002)
31. Gum PA, "A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease", J Am Coll Cardiol, 41, pp.961~965 (2003)
32. Angiolillo DJ, "ADP receptor antagonism: what’s in the pipeline?", Am J Cardiovasc Drugs, 7, pp.423~432 (2007)
33. Pulcinelli FM, "Inhibition of platelet aggregation by aspirin progressively decreases in long-term treated patients", J Am Coll Cardiol, 43, pp.979~984 (2004)
34. Aleil B, "Ticlopidine could be an alternative therapy in the case of pharmacological resistance to clopidogrel: a report of three cases", J Thromb Haemost, 5, pp.879~881 (2007)
35. Douglas JS Jr, "Pharmacologic approaches to restenosis prevention", Am J Cardiol, 100, pp.10~16 (2007)
36. Morishita R, "A scientific rationale for the CREST trial results: evidence for the mechanism of action of cilostazol in restenosis", Atheroscler Suppl, 6, pp.41~46 (2005)
37. Angiolillo DJ, "A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study", Eur Heart J, 29, pp.2202~2211 (2008)
38. Angiolillo DJ, "Randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the Optimizing Antiplatelet Therapy in Diabetes Mellitus (OPTIMUS) study", Circulation, 115, pp.708~716 (2007)
39. Kim JY, "Cilostazol could ameliorate platelet responsiveness to clopidogrel in patients undergoing primary percutaneous coronary intervention", Circ J, 71, pp.1867~1872 (2007)
40. Lee BK, "Effects of triple antiplatelet therapy (aspirin, clopidogrel, and cilostazol) on platelet aggregation and P-selectin expression in patients undergoing coronary artery stent implantation", Am J Cardiol, 100, pp.610~614 (2007)
41. Uchiyama S, "New modalities and aspects of antiplatelet therapy for stroke prevention", Cerebrovasc Dis, 21(Suppl 1), pp.7~16 (2006)
42. Grotemeyer KH, "Two-year follow-up of aspirin responder and aspirin non responder. A pilot-study including 180 post-stroke patients", Thromb Res, 71, pp.397~403 (1993)
43. Helgason CM, "Development of aspirin resistance in persons with previous ischemic stroke", Stroke, 25, pp.2331~2336 (1994)
44. Macchi L, "Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate", Thromb Res, 107, pp.45~49 (2002)
45. Andersen K, "Aspirin non-responsiveness as measured by PFA-100 in patients with coronary artery disease", Thromb Res, 108, pp.37~42 (2002)
46. Wang JC, "Incidence of aspirin nonresponsiveness using the Ultegra Rapid Platelet Function Assay-ASA", Am J Cardiol, 92, pp.1492~1494 (2003)
47. Chen WH, "Aspirin resistance and adverse clinical events in patients with coronary artery disease", Am J Med, 120, pp.631~635 (2007)
48. Hurlen M, "The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction", Scand Cardiovasc J, 32, pp.233~237 (1998)
49. Buchanan MR, "Individual variation in the effects of ASA on platelet function: implications for the use of ASA clinically", Can J Cardiol, 11, pp.221~227 (1995)
50. Mueller MR, "Variable platelet response to low-dose ASA and the risk of limb deterioration in patients submitted to peripheral arterial angioplasty", Thromb Haemost, 78, pp.1003~1007 (1997)
51. Grundmann K, "Aspirin non-responder status in patients with recurrent cerebral ischemic atacks", J Neurol, 250, pp.63~66 (2003)
52. Buchanan MR, "Results of the BRAT study--a pilot study investigatng the possible significance of ASA nonresponsiveness on the benefits and risks of ASA on thrombosis in patients undergoing coronary artery bypass surgery", Can J Cardiol, 16, pp.1385~1390 (2000)

관련 논문AI추천